美国提出加速医疗科技创新成果应用政策建议

2016-04-06 袁天蔚 中国科学报

日前,在美国医药研究与制造商协会(PhRMA)2016 年年会上,PhRMA 主席兼CEO Stephen J. Ubl 宣布了该组织加速医疗科技创新成果应用的政策建议框架。 政策建议的主要内容包括以下四点。第一,药物研发过程现代化。美国食品和药品监督管理局在患者、科学和市场准入方面的改革,将加强生物制药的市场竞争力,提高药物研发的效率,降低消费者用药成本。第二,推动基于价值驱动的健康护理,确保

日前,在美国医药研究与制造商协会(PhRMA)2016 年年会上,PhRMA 主席兼CEO Stephen J. Ubl 宣布了该组织加速医疗科技创新成果应用的政策建议框架。

政策建议的主要内容包括以下四点。第一,药物研发过程现代化。美国食品和药品监督管理局在患者、科学和市场准入方面的改革,将加强生物制药的市场竞争力,提高药物研发的效率,降低消费者用药成本。第二,推动基于价值驱动的健康护理,确保更多患者获得适宜他们的最佳治疗方案。第三,消费者融入和消费者权利要提升。知情的患者也是融入药物研发过程和权利得到提升的消费者,需要确保信息的公开,同时保证信息和隐私安全。第四,解决市场畸形问题。医疗市场中的畸形问题,如美国340B 药品法案导致的一些问题,需要得到纠正。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]
    2016-09-09 wgx306
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]
    2016-09-22 ylzr123

    赞一个!好文章拜读了,认真学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]
    2016-04-08 bioon3
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]
    2016-04-08 mnda
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922154, encodeId=7225192215482, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Fri Sep 09 19:42:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=133248, encodeId=2bc21332480b, content=赞一个!好文章拜读了,认真学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Thu Sep 22 22:27:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260179, encodeId=ad8e12601e90b, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285247, encodeId=e5d3128524ed1, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536841, encodeId=3e14153684154, content=<a href='/topic/show?id=85dc3511216' target=_blank style='color:#2F92EE;'>#医疗科技#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35112, encryptionId=85dc3511216, topicName=医疗科技)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=512412728529, createdName=mnda, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1617613, encodeId=79b7161e613bc, content=<a href='/topic/show?id=9e9ce4939a5' target=_blank style='color:#2F92EE;'>#科技创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74939, encryptionId=9e9ce4939a5, topicName=科技创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2cf19789758, createdName=12498bf3m31暂无昵称, createdTime=Fri Apr 08 00:42:00 CST 2016, time=2016-04-08, status=1, ipAttribution=)]

相关资讯

国内还在用有粉医用手套么?美国或已全面封禁

美国FDA计划停用有粉医用手套小编从《今日医学新闻》中了解到常用于医学检查或临床诊断的一次性有粉医用手套将在美国率先全面封禁。医用手套主要有无粉末和有粉末两种之分。而有粉手套早期因其穿脱方便而受到医生的青睐,但关于有粉手套所致伤口肉芽肿及术后粘连等问题的报道不绝于耳,或基于此美国FDA终于下决心放“大招”。在21日公布了一项提议,拟在全美禁用医用有粉手套。“颁布这个禁令的主要目的是为了保护患者和医

Zika病毒知多少

在拉丁美洲和加勒比海地区,一种罕见的热带病正在流行。蚊子传播的Zika病毒通常导致轻微的疾病,但会导致出生缺陷和其他健康问题。有些事要知道:ZIKA病毒是什么?1947年,乌干达,首次在猴子体内发现Zika病毒;发现地位于Zika森林,故以此命名。去年在巴西、许多拉丁美洲国家和加勒比群岛已经发现Zika病毒踪迹。ZIKA病毒是如何传播的?它与其他热带病如登革热、基孔肯雅和黄热病一样,主要是通过蚊子

万里高空,十小时护航:葛均波院士飞机上救治美国心衰乘客

3月31日,在上海浦东飞往美国芝加哥的UA836航班上,中国科学院院士、复旦大学附属中山医院心内科主任葛均波救治了一名70多岁、房颤复发导致心衰的美国乘客。该乘客1年前因房颤接受过心脏电复律治疗,在起飞4小时左右出现胸闷、出冷汗等症状。葛院士在听到机上广播的求助后立即赶到该乘客身旁,在缺医少药(甚至连听诊器都不给力)的万米高空,展开了快速、积极的救治。他给予该乘客吸氧,并利用飞机上仅有的硝酸甘油酯类药物扩张其血管,同时积极协调乘务人员将其从经济舱移至商务舱,从而能平卧增加回心血量(纠正:这是原记者写的,实际上,让患者进商务舱目的是让患者更舒适、放松)。经过10个小时的悉心照顾,美国乘客的症状有所好转,顺利抵达目的地。葛院士对此表示,“应该做的,因为我们是医生”。

小樵大夫在美国:哪些迷思正在“阻挠”规培?

原标题:规培顺利推行亟需破解迷思 ▲美国南加州大学医学院   乔人立 住院医师规范化培训( 规培),是国家下定决心要推行的制度。这本是一件举国欢庆的好事。岂料,规培之举却激起不少争论,许多反对意见甚至来自医学界资深人士。稍加分析,持反对意见者往往振振有词也是有感而发。很显然,只有彻底破解迷思,消除误解,规培才能顺利进行。 医学的社会功能究竟是什么?

梅奥:惊呆!只有2.7%的人生活方式健康,你呢?

新的的研究发现只有2.7%的美国成人符合科学家承认的全部4个基本的“健康生活方式”标准。如果你是这小部分的人群,自尊心可能会受到极大的鼓舞,不健康的生活方式对人们的危害实在太大。俄勒冈州立大学的研究领导者指出:“我们衡量健康行为的标准是非常合理的,并不是很高,我们不是为了挑选马拉松运动员。”

美国人也说跳广场舞好

今年的两会上,全民健身再掀热潮。过去的一年,广场舞虽然不时有扰民争议,但依然是最热门的群众健身方式之一。而美国学者的研究无疑会给热爱广场舞的人们更大动力。 据《中国循环杂志》报道,近期美国芝加哥学者研究认为:广场舞可以让人更健康。这项研究纳入了65岁左右不爱动的老年人,他们或一周跳两次拉丁舞(研究者根据老人种族文化背景设定的),或去参加健康教育。4个月后,研究者发现,